

1 **Emergence of the SARS-CoV-2 B.1.1.7 lineage and its characteristics at an outpatient**  
2 **testing site in Berlin, Germany, January-March 2021**

3

4 Welmoed van Loon<sup>1</sup>, Heike Rössig<sup>2</sup>, Susen Burock<sup>3</sup>, Jörg Hofmann<sup>4</sup>, Julian Bernhardt<sup>1</sup>,  
5 Elizabeth Linzbach<sup>1</sup>, Domenika Pettenkofer<sup>1</sup>, Christian Schönfeld<sup>1</sup>, Maximilian Gertler<sup>1</sup>,  
6 Joachim Seybold<sup>2</sup>, Tobias Kurth<sup>5</sup>, Frank P. Mockenhaupt<sup>1</sup>

7

8 1 Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin  
9 Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,  
10 Berlin, Germany

11 2 Medical Directorate, Charité - Universitätsmedizin Berlin, corporate member of Freie  
12 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

13 3 Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, corporate  
14 member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

15 4 Labor Berlin - Charité Vivantes GmbH, Berlin, Germany

16 5 Institute of Public Health, Charité-Universitätsmedizin Berlin, corporate member of Freie  
17 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

18

19 **Corresponding author:** Welmoed van Loon, [welmoed.van-loon@charite.de](mailto:welmoed.van-loon@charite.de)

20

21 **Abstract**

22 Within five weeks in early 2021, B.1.1.7 became the dominant SARS-CoV-2 lineage at an  
23 outpatient testing site in Berlin. Characteristics including Ct-values of 193 and 125 recently ill  
24 outpatients with B.1.1.7 and wildtype virus, respectively, were similar, except for more  
25 commonly reported sore throat and travel, and less frequently stated loss of smell and taste in  
26 the former.

27 The SARS-CoV-2 B.1.1.7 lineage (variant of concern [VOC] 202012/01, or 20I/501Y.V1)  
28 likely emerged during autumn 2020 in the United Kingdom and quickly became the dominant  
29 strain (1). It carries multiple mutations and deletions, including 501Y and deletion  
30  $\Delta$ H69/ $\Delta$ V70 (del69–70) in the spike protein. The B.1.1.7 variant is considered to exhibit  
31 increased transmissibility compared to non-VOC lineages (1), hereafter referred to as  
32 wildtype virus, whereas increased fatality is ambiguous (2,3).

33 At the outpatient SARS-CoV-2 testing site of Charité - Universitätsmedizin Berlin, the  
34 first patient infected with the B.1.1.7 variant was identified on January 18, 2021. Herein, we  
35 describe lineage prevalence over time as well as demographic and clinical characteristics in  
36 outpatients with the B.1.1.7 variant and those with the wildtype virus presenting until end of  
37 March. Ethical approval for the analysis was obtained from Charité's institutional review  
38 board (EA4/083/20).

39

#### 40 **The study**

41 Details of the testing site have been described (4). Upon presentation, physicians interviewed  
42 patients on demographics, medical history, and symptoms. If indicated, a combined oro-  
43 nasopharyngeal swab was collected. SARS-CoV-2 infection was assessed applying a cobas®  
44 6800/8800 analyzer (Roche Diagnostics, Mannheim, Germany), targeting both *ORF1ab* and *E*  
45 *Gene* (5). All positive samples were typed for the N501Y and del69–70 polymorphisms by  
46 melting curve analysis. Variants including both polymorphisms were considered B.1.1.7.

47 Between January 18 and March 29, 2021, 349 SARS-CoV-2 positive patients  
48 presented. In this period, the proportion of the B.1.1.7 variant increased from 2% to >90%  
49 (Figure 1). In total, 35.8% (125/349) of the samples belonged to the wildtype lineage, 57.0%  
50 (199/349) were the B.1.1.7 variant, and 7.2% (25/349) other non-wildtype variants (non-  
51 VOCs).

52 Six patients previously had received  $\geq 1$  SARS-CoV-2 vaccination (five, first dose  
53 AZD1222 [Oxford-AstraZeneca] 4-24 days before; one, second BNT162b2  
54 [Pfizer/BioNTech] dose 66 days before); all were infected with B.1.1.7 and were excluded  
55 from analysis as were patients carrying lineages other than wildtype or B.1.1.7. Half of the  
56 patients were female (49%); mean age was  $36 \pm 15$  years. Almost all reported symptoms  
57 (97%). Median symptom duration until testing was 3 days (IQR, 2, 4). Leading complaints  
58 were fatigue (72%), headache (69%), and muscle ache (60%). Fifteen percent reported travel

59 outside of Berlin in the last fourteen days, and half (49%) had had contact with a confirmed  
60 SARS-CoV-2 case (Table 1).

61 Most assessed characteristics did not substantially differ between patients carrying the  
62 SARS-CoV-2 wildtype or the B.1.1.7 lineage, including age, sex, leading complaints,  
63 symptom duration, contacts to a confirmed case, and time passed since such contacts (Table  
64 1). However, B.1.1.7 patients had travelled more frequently than those infected with the  
65 wildtype strain (19% vs. 10%). As for symptoms, patients with B.1.1.7 more often reported  
66 sore throat than those with the wildtype lineage (54% vs. 42%) but less often loss of  
67 smell/taste (24% vs. 38%) (Table 1).

68 We observed no difference in cycle threshold (Ct)-values for the *E Gene* target  
69 between B.1.1.7 and wildtype samples (medians, 20.2 vs. 20.1) (Table 1). In patients reporting  
70 a symptom duration of  $\geq 7$  days, Ct-values appeared to be lower for the B.1.1.7 lineage  
71 (median, 26.2; wildtype, 30.1; Mann-Whitney-U-test,  $P=0.7$ ) (Table 1, Figure 2).

72 Lastly, we explored which combination of variables in our dataset best predicted the  
73 B.1.1.7 variant in a logistic regression applying a backward stepwise selection based on the  
74 Akaike information criterion. This identified the best set of predictors as absent loss of  
75 smell/taste ( $P=0.01$ ), longer symptom duration ( $P=0.02$ ), sore throat ( $P=0.05$ ), lower Ct-  
76 value ( $P=0.07$ ), travel in the last 14 days ( $P=0.08$ ), lower age ( $P=0.09$ ), and absent  
77 rhinorrhea ( $P=0.12$ ). We then used bootstrap technique to repeat the variable selection in  
78 1,000 replicated datasets and evaluated how often these variables were selected with the  
79 backward selection. This resulted in loss of smell/taste, 89%; symptom duration, 78%; travel,  
80 73%; sore throat, 68%; Ct-value, 66%; age, 56%; rhinorrhea, 51%. Absent loss of smell/taste,  
81 longer symptom duration, and travel were selected most often, indicating their importance in  
82 B.1.1.7 variant prediction. All analyses were done in R version 3.6.3.

83

## 84 **Discussion**

85 The first B.1.1.7 case in Germany was notified in late December 2020 (6). At our testing site,  
86 the B.1.1.7 lineage was first observed three weeks later and replaced the wildtype virus as the  
87 dominant strain within five weeks only. The rapid emergence and dominance of this lineage  
88 likely results from its increased transmissibility (1), which is potentially caused by spike  
89 protein polymorphisms including 501Y conferring enhanced mucosal binding (7); 681H, near  
90 a region important for transmission (8); deletion 69-70, linked to immune escape (9). Viral  
91 replication *in vitro* does not differ from pre-existing strains (10).

92 The B.1.1.7 variant reportedly is associated with increased mortality (2), although this  
93 has been questioned (3). In our young outpatient study population, we did not observe major,  
94 lineage-dependent differences in leading symptoms. Nevertheless, loss of smell/taste, among  
95 the most specific COVID-19 symptoms (4), was less common in patients infected with  
96 B.1.1.7., whereas, sore throat was more frequently reported than in wildtype virus patients.  
97 Similarly, a UK survey revealed less loss of smell/taste in B.1.1.7 patients but more sore  
98 throat, cough, fatigue, myalgia, and fever (11). In contrast, no associations between SARS-  
99 CoV-2 B.1.1.7 and self-reported symptoms, disease duration, or hospital admissions were  
100 seen in another UK study (12). The most important factors for B.1.1.7 infection prediction in  
101 our study appeared to be loss of smell/taste and longer symptom duration, in addition to  
102 recent travel.

103 As for Ct-values, one study observed similar figures in patients infected with B.1.1.7  
104 and wildtype lineages; however, a longer duration of infection with the B.1.1.7 variant was  
105 suggestive by repeated sampling over time (13). Likewise, longer persistence has been  
106 observed for B.1.1.7 (14), but also lower Ct-values (higher viral load) compared to wildtype  
107 samples. Lower Ct-values were also seen in other studies on population (15) and inpatient  
108 levels (3). In our cross-sectional assessment of recently ill outpatients, we did not observe  
109 such differences. Still, increased transmissibility may result from the variant's prolonged  
110 excretion (13,14). Test timing appears crucial for the interpretation of Ct-values. Outpatients  
111 are commonly tested earlier in the course of infection than inpatients. The combination of  
112 prolonged viral shedding with different test timing might explain increased viral load in  
113 B.1.1.7 samples in inpatients, but not in recently ill outpatients. In support of that, in our  
114 outpatients with  $\geq 7$  days symptom duration, Ct-values in B.1.1.7 samples were suggestively  
115 reduced. However, the comparison groups were small. Our data enable to detect a maximum  
116 effect size on overall Ct-values, which corresponds to B.1.1.7 Ct-values being 1.5 units below  
117 wildtype, or 1.0 above.

118 The main limitation in our study are limited subgroup sizes, which reduced the  
119 likelihood to detect differences between rare characteristics. Others are the one-time  
120 assessment, subjective symptom duration, and the variable manifestation of SARS-CoV-2  
121 infection (4). Strengths include standardized procedures conducted by trained medical staff  
122 and the prospective nature of the study evaluating patient groups during the same time period,  
123 reducing the likelihood of confounding due to temporal effects.

124 SARS-CoV-2 VOC B.1.1.7 is now the dominant lineage in Berlin. On the outpatient  
125 level, there appears to be no major difference in clinical manifestation.

126

127 **Acknowledgments**

128 We thank the Corona Untersuchungsstelle (CUS) staff at the Charité - Universitaetsmedizin  
129 Berlin for their dedication and hard work during the COVID-19 pandemic.

130

131 **References**

- 132 1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Hopkins S, et al.  
133 Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from  
134 linking epidemiological and genetic data. MedRxiv [Preprint]. 2021 [cited 2021  
135 Apr 1]. Available from:  
136 <https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2>.
- 137 2. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ,  
138 Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases  
139 of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar 15;1–5. doi:  
140 10.1038/s41586-021-03426-1.
- 141 3. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic  
142 characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage  
143 in London, UK: a whole-genome sequencing and hospital-based cohort study.  
144 Lancet Infect Dis. 2021 Apr 12;0(0). doi: 10.1016/S1473-3099(21)00170-5.
- 145 4. Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, et al.  
146 Epidemiological and clinical characteristics of SARS-CoV-2 infections at a  
147 testing site in Berlin, Germany, March and April 2020—a cross-sectional study.  
148 Clin Microbiol Infect. 2020 Dec;26(12):1685.e7-1685.e12. doi:  
149 10.1016/j.cmi.2020.08.017.
- 150 5. Poljak M, Korva M, Gašper NK, Komloš KF, Sagadin M, Uršič T, et al. Clinical  
151 evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch  
152 during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020  
153 May 26;58(6):e00599-20. doi: 10.1128/JCM.00599-20.
- 154 6. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation  
155 Report of the Robert Koch Institute. 26/12/2020. 2020. Available from:  
156 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Situationsber  
157 chte/Dez\\_2020/2020-12-26-en.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Dez_2020/2020-12-26-en.pdf?__blob=publicationFile)
- 158 7. Chan KK, Tan TJC, Narayanan KK, Procko E. An engineered decoy receptor for  
159 SARS-CoV-2 broadly binds protein S sequence variants. Sci Adv. 2021 Feb  
160 17;7(8):eabf1738. doi: 10.1126/sciadv.abf1738.
- 161 8. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The  
162 furin cleavage site of SARS-CoV-2 spike protein is a key determinant for  
163 transmission due to enhanced replication in airway cells. BioRxiv [Preprint];

- 164 2020 [cited 2021 Apr 14]. Available from:  
165 <https://doi.org/10.1101/2020.09.30.318311>.
- 166 9. Kemp SA, Collier DA, Datir R, Ferreira IATM, Gayed S, Jahun A, et al.  
167 Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. *Nature*.  
168 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y.
- 169 10. Brown JC, Goldhill DH, Zhou J, Peacock TP, Frise R, Goonawardane N, et al.  
170 Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is  
171 not accounted for by a replicative advantage in primary airway cells or antibody  
172 escape. *BioRxiv [Preprint]*. 2021 [cited 2021 Apr 3]; Available from:  
173 <https://doi.org/10.1101/2021.02.24.432576>.
- 174 11. Office for National Statistics. Coronavirus (COVID-19) Infection Survey:  
175 characteristics of people testing positive for COVID-19 in England. 2021.  
176 Available from:  
177 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/co](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)  
178 [nditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengl](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)  
179 [and/characteristicsofpeopletestingpositiveforcovid19inengland27january2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)
- 180 12. Graham MS, Sudre CH, May AM, Antonelli M, Murray B, Varsavsky T, et al.  
181 Changes in symptomatology, re-infection and transmissibility associated with  
182 SARS-CoV-2 variant B.1.1.7: an ecological study The COVID-19 Genomics  
183 UK (COG-UK) consortium. *MedRxiv [Preprint]*. 2021 [cited 2021 Apr 1];  
184 Available from:  
185 <https://www.medrxiv.org/content/10.1101/2021.01.28.21250680v2>.
- 186 13. Kissler SM, Fauver JR, Mack C, Tai CG, Watkins AE, Samant RM, et al.  
187 Densely sampled viral trajectories suggest longer duration of acute infection  
188 with B.1.1.7 1 variant relative to non-B.1.1.7 SARS-CoV-2 2 3. *MedRxiv*  
189 *[Preprint]*. 2021 [cited 2021 Mar 30]; Available from:  
190 <https://doi.org/10.1101/2021.02.16.21251535>.
- 191 14. Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al.  
192 Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by  
193 longer persistence and higher viral RNA loads in nasopharyngeal swabs. *Int J*  
194 *Infect Dis*. 2021 Mar 5;105:753-755. doi: 10.1016/j.ijid.2021.03.005.
- 195 15. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant  
196 SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in

197 samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis. 2021 Feb  
198 13:jiab082. doi: 10.1093/infdis/jiab082.  
199


200 **Table 1. Characteristics of SARS-CoV-2 positive outpatients attending the Charité**  
 201 **testing site, separated by wildtype and B.1.1.7 lineages**

	Wildtype lineage N=125 (%, mean [SD], or median [25 <sup>th</sup> , 75 <sup>th</sup> quantile])	B.1.1.7 variant N=193 (%, mean [SD], or median [25 <sup>th</sup> , 75 <sup>th</sup> quantile])	OR [95%CI], difference in mean [95%CI], or difference in median [95%CI]*
Female	44.8%	51.0%	1.3 (0.8, 2.0)
Age, years	36.6 (13.8)	34.8 (15.9)	1.8 (-1.5, 5.1)
Any symptoms	97.6%	96.4%	0.7 (0.2, 2.6)
Self-reported fever in the last 48 hours	38.4%	42.5%	1.2 (0.8, 1.9)
Temperature in case of fever (°C, by patient statement)	38.3 (0.6)	38.2 (0.7)	0.1 (-0.2, 0.4)
Short of breath	9.6%	13.5%	1.5 (0.7, 3.0)
Fatigue	73.6%	71.5%	0.9 (0.5, 1.5)
Pain on the chest	2.4%	1.0%	0.4 (0.1, 2.6)
Diarrhea	15.2%	12.4%	0.8 (0.4, 1.5)
Loss of smell/taste	37.6%	23.8%	0.5 (0.3, 0.9)
Muscle ache	60.0%	60.1%	1.0 (0.6, 1.6)
Sore throat	41.6%	53.9%	1.6 (1.0, 2.6)
Cough	48.8%	50.8%	1.1 (0.7, 1.7)
Headache	68.8%	68.9%	1.0 (0.6, 1.6)
Chills	35.2%	34.7%	1.0 (0.6, 1.6)
Rhinorrhea	60.8%	52.8%	0.7 (0.5, 1.1)
Symptom duration upon test (days)	3.0 (2.0, 4.8)	3.0 (2.0, 4.0)	0.0 (-1.0, 0.0)
Contact to a confirmed SARS-CoV-2 case	48.0%	50.3%	1.1 (0.7, 1.7)
Time between contact to a confirmed SARS-CoV-2 case and test (days)	4.0 (1.2, 7.0)	4.0 (1.0, 6.0)	0.0 (-1.5, 3.0)
Traveled outside the	9.6%	18.7%	2.2 (1.1, 4.3)

	Wildtype lineage	B.1.1.7 variant	OR [95%CI], difference in mean [95%CI], or difference in median [95%CI]*
	N=125	N=193	
	(%, mean [SD], or median [25 <sup>th</sup> , 75 <sup>th</sup> quantile])	(%, mean [SD], or median [25 <sup>th</sup> , 75 <sup>th</sup> quantile])	
<hr/>			
Berlin region in the last 14 days			
Ct-value	20.2 (17.4, 24.1)	20.1 (17.1, 22.8)	0.1 (-0.9, 1.6)
Symptom duration < 7 days	N=113; 19.9 (17.4, 23.5)	N =171; 19.5 (16.6, 22.6)	0.4 (-1.0, 1.7)
Symptom duration ≥ 7 days	N=6; 30.1 (26.1, 31.3)	N=11; 26.2 (21.4, 31.2)	3.9 (-5.6, 10.0)

202 \* The 95% confidence interval for the difference in medians was computed by a percentile  
203 bootstrap with 1,000 replications.


204



205

206 **Figure 1. Proportion of SARS-CoV-2 lineages at the Charité testing site, 2021.** The  
 207 numbers on top of the bars indicate the total number of positive SARS-CoV-2-tests assessed.  
 208 Six (partially) vaccinated outpatients are included for completeness. Note that calendar week  
 209 13 only includes one day (March 29).

210



211

212 **Figure 2. Comparison of median Ct-values in SARS-CoV-2 wildtype and B.1.1.7 lineage,**  
 213 **by symptom duration.** The boxplots indicate medians, 25<sup>th</sup> and 75<sup>th</sup> percentiles (i.e., Q1 and  
 214 Q3). The upper whiskers reach the largest value with a maximum  $Q3 + 1.5 * \text{interquartile}$   
 215  $\text{range (IQR)}$ . The lower whiskers reach the smallest value with a minimum  $Q1 - 1.5 * \text{IQR}$ .  
 216 The numbers on top of the boxplots indicate the total number of observations included in the  
 217 comparison.